CytomX Therapeutics CTMX Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$18.25M+31.2% | -$26.51M-86.3% | -$14.23M-9,140% | -$154K-101% | $23.53M+24.6% | ||
| $4.71M+218% | $1.48M+6.9% | $1.38M-3.3% | $1.43M-28.7% | $2.01M+6.6% | ||
| -$1.37M— | —— | -$240K-176% | -$87K+92.4% | -$1.15M-361% | ||
| $67K-89.8% | $655K+56.3% | $419K+955% | -$49K+93.9% | -$804K-208% | ||
| $887K+1.5% | $874K— | —— | —— | $1.2M— | ||
| -$9.61M— | $0+100% | -$4.38M+74.5% | -$17.15M+61.6% | -$44.62M-25.5% | ||
| $37K0.0% | $37K+2.8% | $36K-2.7% | $37K+2.8% | $36K-2.7% | ||
| -$25.55M-9.9% | -$23.24M-49.5% | -$15.55M+1.3% | -$15.75M+25.1% | -$21.04M-5.7% | ||
| $0-100% | $201K— | —— | $27K-77.3% | $119K+48.8% | ||
| $242.78M+449% | $44.22M+125% | $19.69M-81.9% | $108.83M+450% | $19.79M-60.3% | ||
| $50M+66.7% | $30M+50.0% | $20M-38.5% | $32.5M-35.6% | $50.5M-22.3% | ||
| -$192.78M-1,237% | -$14.42M— | $0+100% | -$76.36M-350% | $30.6M+102% | ||
| $228.35M+1,304% | $16.26M— | $0-100% | $93.4M— | $0-100% | ||
| $234.49M+1,309% | $16.64M+6,478% | $253K-99.7% | $93.55M— | $0-100% | ||
| $16.16M+177% | -$21.02M-41.5% | -$14.86M-1,134% | $1.44M-85.0% | $9.55M— | ||
| $726K+1.0% | $719K+13.1% | $636K+60.2% | $397K-12.6% | $454K-42.3% | ||
| $37K0.0% | $37K+2.8% | $36K-2.7% | $37K+2.8% | $36K-2.7% | ||
| $214K-54.8% | $473K+383% | $98K-68.4% | $310K-11.2% | $349K-7.2% | ||
| —— | -$100.5K0.0% | -$100.5K0.0% | -$100.5K0.0% | -$100.5K-279% | ||
| -$3.6M— | —— | -$326K+70.4% | -$1.1M+47.6% | -$2.11M+62.1% | ||
| $887K+1.5% | $874K— | —— | —— | $1.2M— | ||
| -$1.13M+2.5% | -$1.16M-2.5% | -$1.13M-2.3% | -$1.11M-2.5% | -$1.08M-2.3% | ||
| $242.78M+449% | $44.22M+125% | $19.69M-81.9% | $108.83M+450% | $19.79M-60.3% | ||
| $50M+66.7% | $30M+50.0% | $20M-38.5% | $32.5M-35.6% | $50.5M-22.3% | ||
| $281K-26.2% | $381K+50.6% | $253K+42.9% | $177K— | $0-100% | ||
| $780K— | —— | —— | —— | $0— | ||
| -$9.61M— | $0+100% | -$4.38M+74.5% | -$17.15M+61.6% | -$44.62M-25.5% | ||
| —— | $750.5K0.0% | $750.5K0.0% | $750.5K0.0% | $750.5K— | ||
| $5.86M— | —— | —— | —— | $0— | ||
| -$25.55M-9.0% | -$23.44M-52.0% | -$15.42M+2.3% | -$15.78M+25.4% | -$21.16M-5.9% | ||
| -$25.55M-9.0% | -$23.44M-52.0% | -$15.42M+2.3% | -$15.78M+25.4% | -$21.16M-5.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does CytomX Therapeutics generate?
- CytomX Therapeutics (CTMX) generated -$80.1M in operating cash flow over the trailing twelve months.
- What is CytomX Therapeutics's free cash flow?
- After $347.0K of capital expenditures, CytomX Therapeutics's free cash flow was -$80.2M over the trailing twelve months, up 1.7% year over year.
- Where does CytomX Therapeutics's cash flow data come from?
- Every line is extracted from CytomX Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
